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The transcription factor T-box-expressed-in-T-cells (T-bet) is required for TH1 lymphocyte
differentiation, regulates the IL-12-induced expression of the TH1-specific cytokine IFNg
and may be dysregulated in asthmatics.
The modulatory role of extracellular signal-regulated kinase (ERK)-1/-2, p38mitogen-
activated protein kinase (MAPK) and dexamethasone on IL-12 induced T-bet and IFNg
expression was assessed in peripheral blood lymphocytes of 10 atopic asthmatics and 10
nonatopic normals.
IFNg production was dependent on phosphorylation of ERK-1/-2 and p38MAPK, as examined
by PD098059, an inhibitor of the upstream activator of MAPKkinase (MKK-1), and SB203580,
an inhibitor of p38MAPK. The inhibitory effect of PD098059 on IFNg release was decreased
in asthmatic T-cells compared with normals.
The IL-12-induced T-bet expression and the inhibitory effect of SB203580 were increased in
asthmatic T-cells compared with normals.
Dexamethasone blocked the IL-12-induced T-bet expression in asthmatic T-cells
completely and decreased IL-12-induced IFNg release by 50%, which occurred to the
same extent in asthmatic and normal T-cells.
In conclusion, (1) p38MAPK-pathway rather than ERK-pathway may play a more basic role
in the regulation of the increased T-bet expression in asthma, and (2) ERK- and p38MAPK-
activation modulate IFNg expression independently of T-bet and this regulatory role ofElsevier Ltd. All rights reserved.
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on T-bet and IFNg production seems to be critical.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Naı¨ve CD4+ T-lymphocytes, upon stimulation with antigens in
the appropriate environment, differentiate into two classes
of effector cells, TH1 and TH2. Increased numbers of CD4
+
T-cells expressing IL-4 and IL-5 mRNA have been found in
bronchoalveolar lavage (BAL)1–3 and in nasal and bronchial
mucosa4,5 from allergic subjects. It has been demonstrated
that peripheral blood lymphocytes from asthmatic subjects
are primed for enhanced productions of IL-4 and IL-5 mRNA6
and GATA-3 DNA7 indicating a TH2-predominance in asthma.
IFNg, a major cytokine from TH1 cells, directly suppresses
IgE synthesis and inhibits the development toward TH2
cells.8,9 In young children with atopic disease, the reduction
of IFNg secretion was demonstrated.10,11 Infants whose cord
blood cells had shown diminished IFNg production in vitro
were susceptible to the subsequent development of atopy.12
Furthermore, TH1-cells produce IFNg to participate in cell-
mediated immunity that controls infection by intracellular
pathogens. The predominant factors that control TH1
differentiation are cytokines such as IL-12 to stimulate and
IL-4 to inhibit TH1 differentiation.
The transcription factor T-box-expressed-in-T-cells
(T-bet) has recently been described as a TH1-specific factor
that plays a central role in TH1 differentiation.
13 T-bet was
described as a controller of TH1 development and was shown
to have direct effects in IL-12 receptor b2 chain expression
and IFNg production.14–17 Additionally, transfection of T-bet
into TH2 cells induced high levels of IFNg and suppressed IL-5
and IL-4 generation.18 Finotto et al.19 described reduced
numbers of cells staining for T-bet in bronchial biopsy
specimens from asthmatic patients. Furthermore loss of
T-bet results in increased airway hyperreactivity (AHR), an
increased peribronchial and perivascular infiltration of
eosinophils and lymphocytes, a greater amount of collagen
around the airways and increased immunostaining of
myofibroblasts in the airways of mice deficient in T-bet.
So the authors speculate that a defect in TH1 development
through a deficiency in T-bet might predispose to
TH2-responses.
However, recent data argue against this model.20–22
Ylikoski et al.23 reported that in normal human cord blood
IL-12 signaling is able to induce T-bet mRNA and protein
expression during the early polarization of human CD4+
T-cells to TH1 direction and a likely mechanism behind it is
IL-12 induced STAT1 tyrosine phosphorylation. Recently,
Hwang et al.24 reported that T-bet represses TH2 lineage
commitment through tyrosine kinase-mediated interaction
between the two transcription factors that interferes with
the binding of GATA-3 to its target DNA providing a novel
function for tyrosine phosphorylation of T-bet and revealed
that the role of T-bet tyrosine phosphorylation in repressing
TH2 cytokines is independent of IFNg. Moreover, Usui
et al.20,25 could demonstrate in mice that naı¨ve T-cells tendtoward TH2 differentiation through induction of GATA-3 and
subsequent down-regulation of STAT4/IL-12Rb2 chain unless
GATA-3 levels or function is regulated by T-bet indicating
that the principal function of T-bet in developing TH1 cells is
to negatively regulate GATA-3 rather than to positively
regulate IFNg gene. They also could shown that developing
TH2 cells from T-bet / mice could differentiate into TH1
cells when STAT4 and IL-12Rb2 chain expression are
maintained.25
Regulation of transcription of immunomodulatory and
inflammatory genes such as T-bet in response to extra-
cellular stimuli is achieved by a variety of different signal
transduction mechanisms. One of the most extensively
studied signaling pathways into the nucleus involves the
mitogen-activated protein (MAP) kinase (MAPK) cascade.26
At present there are at least three MAP kinase pathways
which are defined according to the MAP kinase that is
activated (a) the extracellular signal regulated protein
kinase (ERK)-1 and -2 pathway, (b) the c-Jun N-terminal
protein kinase (JNK) pathway and (c) the p38mitogen-
activated protein kinase (p38MAPK) pathway. These are
activated by different stimuli including growth factors,
endotoxins, stress, pharmacological agonists and cytokines
such as IL-12.27,28 A number of recent studies have
demonstrated a major role for the components of the
MAPK pathway in the regulation of innate and adaptive
immune responses including TH1/TH2 differentiation
29,30 but
little is known about the modulatory role of the MAPkinases
ERK-1/-2 and p38MAPK on T-bet and IFNg expression of
human peripheral blood T-lymphocytes.
Corticosteroids constitute the most effective current anti-
inflammatory therapy for acute and chronic forms of allergic
diseases and asthma. Corticosteroids are highly effective in
inhibiting the effector function of epithelial cells, eosino-
phils and TH2 cells and also in inducing T-cell apoptosis.
31,32
These results are seemingly in conflict with a previous study
by Cannarile et al.33 reporting that glucocorticoid-induced
leucine zipper (GILZ), induced by dexamethasone, is
involved in control of T lymphocyte activation and apoptosis
using GILZ transgenic mice which overexpress GILZ in the
T-cell lineage. Interestingly, those cells secrete more TH2
cytokines (IL-5, IL-13, IL-4) and produce less TH1 cytokines
(IFNg) than wild-type mice. Upregulation of TH2 cytokine
expression correlated with increased expression of TH2
specific transcription factors (GATA-3) and decreased expres-
sion of T-bet indicating that GILZ is implicated in TH2
response development and may be one critical mechanism
accounting for glucocorticoid immunomodulation.33
In the present study, the potential role of the protein
kinases ERK-1/-2 and p38MAPK and dexamethasone in
modulating T-bet expression and IFNg release in human
peripheral T-lymphocytes were examined. As T-bet may be a
potent inducer of the TH1 specific cytokine IFNg, we were
interested in measuring whether the amount of IFNg
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normal and asthmatic individuals.Materials and methods
Subjects
The study population consisted of 10 healthy non-atopic
non-smoking volunteers (four males, six females; mean age:
30.772.4 years), who had no history of asthma or of any
respiratory disease with normal lung function and airway
responsiveness to methacholine (PC20416mg/ml) and 10
mild atopic asthmatics (five males, five females; mean age:
28.872.8 years) with an airway hyperresponsiveness to
methacholine (PC20o8mg/ml); positive PRICK- or RAST-
tests for house dust mite etc. were included in this study
(Table 1). All volunteers underwent peripheral blood
separation after giving written informed consent. The study
was approved by the Ethics Committee of the University of
Cologne.Isolation of human peripheral blood lymphocytes
A total of 50ml of peripheral venous blood from 10 non-
atopic normals and 10 atopic asthmatics were drawn into
sterile syringes (Becton Dickinson, Franklin Lakes, NY, cat#
300296) by veinpuncture with anticoagulant–citrate–dex-
trose (ACD) solution as anticoagulant at a final concentra-
tion of 10% (v/v). (ACD: 277mM D-(+)-glucose; 142mM
tribase sodium citrate). In parallel total venous blood
(2ml) from all subjects were submitted to the laboratory
for differential WBC count (Table 1).Table 1 Characteristics of non-atopic normals and
atopic asthmatic subjects.
Nonatopic
normals
Atopic
asthmatics
Female 6 5
Male 4 5
Age (yr) 30.772.4 28.872.8
FEV1 (% pred.) 102.674.2 92.974.6
IgE (U/l) 56.374.7 284713.4
WBC (103/ml) 7.1370.5 6.4570.59
Lymphocytes (103/ml) 2.1770.1 1.5870.07
Lymphocytes (% WBC) 31.571.9 25.371.5
Eosinophils (103/ml) 0.1670.03 0.4070.14
Eosinophils (% WBC) 2.3070.5 6.5072.2
Monocytes (103/ml) 0.5170.05 0.4170.03
Monocytes (% WBC) 7.1370.5 6.6070.5
Neutrophils (103/ml) 4.3570.4 4.0070.5
Neutrophils (% WBC) 58.672.6 60.873.3
Basophils (103/ml) 0.0370.007 0.0370.007
Basophils (% WBC) 0.5270.1 0.5770.1
WBC, white blood cells; FEV1, forced expiratory volume in
1 s; IgE, immunglobuline E.
Data shown as mean7SEM.The ACD-blood was prepared for sedimentation using
20ml of ELO–HES (6-hydroxyethyl starch) and 5ml of ACD
(10%) per 25ml of ACD-blood. The tubes were inversionly
mixed and air bubbles removed to prevent cell activation
before leaving at room temperature for sedimention of cells
on a vibration free surface for approximately 60min. The
leukocyte-rich plasma fraction was centrifuged at 360g for
10min and 4 1C. The cell pellet was washed twice and then
resuspended in about 2ml of Hank’s balanced Salt Solution
(HBSS, Sigma, St. Louis, MO, cat# H6648). and layered over
7ml of Ficoll-paque (Amersham Pharmacia Biotech, Uppsa-
la, Sweden, cat# 17-1440-02) and centrifuged for 30min at
360g and 18 1C. The band of mononuclear cells (monocytes
and lymphocytes) were collected from the interface and
washed and resuspended three times in HBSS (Hanks
buffered saline solution). After the third wash the cells
were resuspended in RPMI 1640 (Sigma, cat# R-7638),
supplemented with 10% fetal calf serum (FCS; Sigma, cat#
N-4637), 2mM L-glutamine, 100U/ml penicillin, 100 m/ml
streptomycin (all from Sigma, Munich, Germany). Lympho-
cytes were separated from monocytes by depletion of
monocytes by plastic adherence seeding in a culture flask
in culture RPMI1640 medium in a humified atmosphere with
5% CO2 for 3 h. After 3 h, nonadherent cells (lymphocytes)
were separated and used for further analysis. The propor-
tion of CD3+-lymphocytes in this separated cell fraction was
examined by FACS-analysis. The purified T-lymphocytes from
mononuclear cell (MNC) samples were routinely X98% CD3+
lymphocytes. Cells were485% viable, as assessed by trypan
blue exclusion.
FACS analysis
Purified T-lymphocytes from mononuclear cells were incu-
bated with CD14+ conjugated PE-Ab and CD3+ conjugated
FITC-Ab and analyzed by flow cytometry in each test. Cells
were initially gated on the basis of forward scatter and side
scatter characteristics, with gates set to remove debris.
Results were expressed as a percentage of cells exhibiting
positive fluorescence (data not shown).
Cell culture
Peripheral blood T-lymphocytes were cultured at 37 1C in a
humified atmosphere with 5% CO2 in RPMI1640 medium
(Sigma, Munich, Germany) supplemented with 10% (v/v)
FCS, 2mM L-glutamine, 100U/ml penicillin, 100 m/ml strep-
tomycin (all from Sigma, Munich, Germany). After 12 h cells
were stimulated in fresh RPMI medium as above at
1 106 cells/ml for ELISA and with RPMI medium in the
absence of FCS at 3 106 cells/ml for real-time-PCR and for
Western blotting. CD3-purified mouse anti-human monoclo-
nal antibody; (500 ng/ml; BD Becton Dickinson, Heidelberg,
Germany; cat# 555336) and CD28-purified mouse anti-
human monoclonal antibody (500 ng/ml; BD Biosciences;
Germany, cat# 555725) were added 30min before stimula-
tion with IL-12 (10 ng/ml; R&D Systems, Wiesbaden,
Germany; cat# 219-IL-005) for 72 h for ELISA and for 4 h for
real-time-PCR. The ERK-1/-2 inhibitor, PD 098059 (10mM;
Calbiochem-Merck, Darmstadt, Germany, cat# 513000), the
p38MAPK inhibitor SB 203580 (10 mM; Calbiochem-Merck,
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(106 M; Sigma-Aldrich, Munich, Germany, cat# D-4902)
were added 30min before stimulation with IL-12. Drugs
were dissolved in dimethyl sulfoxide (Me2SO) or distilled
water and were diluted to final concentrations of less than
0.1% (v/v). Me2SO alone had no effect on expression or
generation of IFNg, T-bet or EF-1a (data not shown). We have
done time- and concentration-dependent experiments for
all treatments used.
Enzyme-linked immunosorbent Assays (ELISA) for
IFNc
IFNg was assayed using a quantitative sandwich enzyme
immunoassay technique. 96-well plates (NUNC Inc) were
coated overnight at room temperature with 100 ml of a
monoclonal anti-human IFNg antibody (2 mg/ml) (R&D
Systems; Wiesbaden, Germany; cat# MAB285). After washing
with TBS-Tween-20s, the antibody was blocked with PBS/1%
BSA; 5% sucrose (Sigma, Munich, Germany) and 0.05% NaN3
(300 ml/well, Sigma, Munich, Germany) for 1 h. IFNg-stan-
dard (rh IFNg, R&D Systems, cat# 285-IF-100) and a
biotinylated secondary anti-human IFNg antibody (R&D
Systems; cat# BAF285) non-diluted samples were added to
the plate for 2 h at room-temperature and washed with PBS-
Tween-20s four times. A biotinylated secondary anti-human
IFNg antibody (R&D Systems; cat# BAF285) (100 ml of 125 ng/
ml) in PBS/1% BSA was added for 1 h followed by 100 ml
streptavidin-HRP (R&D Systems, cat# DY998). After washing,
100 ml of TMB substrate solution (Sigma, Munich, Germany;
cat# T8665) and 50 ml stop solution (1M H2SO4) (AppliChem,
Darmstadt, Germany, cat# A2699) was added to each well
and IFNg was measured colorimetrically at 450 nm and
quantified by interpolation from a standard curve. The lower
limit of detection was 16 pg/ml.
RT-Real time PCR for T-bet and elongation factor
(EF)—1a
RNA isolation and cDNA synthesis
RNA of T-lymphocytes (3 106 cells) was extracted using
Qiagen kit (RNeasy Mini kit, Qiagen, Hilden, Germany, cat#
74106), according to the manufacturer0s instructions and
RNA was finally eluted in 30 ml nuclease free water. The
concentration and purity of RNA were assessed by spectro-
photometry. 10 mg of RNA was treated with DNase (Promega
Corporation, Madison, WI, USA; cat# M610A) at 37 1C for
15min. After addition of 2 ml of stop solution (Promega
Corporation, Madison, WI, USA cat# M199A) RNA was heat
inactivated at 65 1C for 10min. Reverse transcription of
0.5mg of DNase treated RNA was performed using random
hexamers (Promega Corporation, Madison, WI, USA; cat#
C1181) and Omniscript RT kit (Qiagen, Hilden, Germany,
cat# 205 111) according to the manufaturer’s instruction and
samples were incubated at 37 1C for 60min followed by 93 1C
for 5min. The cDNA was subsequently diluted to a final
volume of 60 ml with nuclease-free water.
Standard-plasmid construction
We generated plasmid-standards to quantify the gene
expression. Plasmids containing a gene region of the T-betor EF-1a genes were created by PCR-mediated cloning. A
backbone pBluescript SK-plasmid (Stratagene, La Jolla, CA,
USA, cat# 212206) was linearized with BamHI and depho-
sphorilized. For the insert production the amplification
primer pairs for the real-time PCR (see below) were
used supplemented with a BamHI-restriction site at the
50 end. With these primers a conventional 3-step PCR
on a lymphocyte cDNA was performed. The obtained inserts
were purified by a gel extraction and followed by a BamHI
digest to obtain sticky ends. The inserts were cloned into
the linearized plasmid-backbone. Subsequently we per-
formed a functional test with the real-time PCR. The
concentration of plasmid-DNA was assessed by spectro-
photometry and the copy number was calculated. Standard
curves for each gene were generated using 10-fold serial
dilutions (102–105 copies/4 ml) including a no template
control.Real-time PCR
Our initial plan to use the expression level of GAPDH in
normalizing the results of T-bet failed. These results were
consistant with those of Hamalainen et al.34 demonstrating
that the transcription of a constitutively expressed gene in
human CD4+ T-cells may change during cell culture in vitro
and this was most pronounced with b-actin (up to 11.4-fold)
and GAPDH (up to 17.0-fold). In contrast the expression of
EF-1a and UbcH5B remained constant during the entire
culture periods.34 Therefore, EF-1a was used in this study to
normalize the T-bet expression.
For real-time PCR, the following intron spanning primer
pairs were used: T-bet forward primer: 50-GAT CAT CAC CAA
GCA GGG ACG-30, T-bet reverse primer: 50-TCC ACA CTG CAC
CCA CTT GC-30, with an amplification length of 154 bp. EF-1a
forward primer: 50-GGG ATG GAA AGT CAC CCG TA-30, EF-1a
reverse primer: 50-GCC GTG TGG CAA TCC AAT-30, with an
amplification length of 461 bp (all from VBC-Genomics
Bioscience Research GmbH, Vienna, Austria). Real time
PCR reaction contained 4 ml cDNA, 0.5mM forward and
reverse primer for T-bet or EF-1a, 4 ml LC-FastStart DNA
Masterplus SYBR Green I—mix (Roche Diagnostics GmbH,
Mannheim, Germany cat# 03515885001) and was diluted
with nuclease free water to a final volume of 20 ml. cDNA
samples, the plasmid-standards and one no-template con-
trol were measured for each gene analysis. PCR amplifica-
tion and quantification were performed in a LightCyclerTM
1.5 instrument (Roche Diagnostics, GmbH, Mannheim,
Germany). After an initial denaturation at 95 1C for 10min,
a three step PCR was performed for 40 cycles: (1)
denaturation at 95 1C for 10 s; (2) annealing at 60 1C for 5 s
and (3) extension at 72 1C for 7 s for T-bet and 20 s for EF-1a.
Fluorescence was detected at the end of each extension
step (SYBR Green format). Melting analysis was performed
following template amplification as a specific control.
Therefore, the amplified product was slowly heated
(0.1 1C/s) from 65 to 95 1C and fluorescence was measured
continuously. Data evaluation was performed using Light-
CyclerTM software version 3.5 according to the suppliers
recommendations. Sample concentration was calculated
using standard curve with plasmid DNA template for each
gene. Relative gene expression was expressed as a ratio of
T-bet copies to EF-1a copies.
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Western blotting
The status of T-bet and GAPDH were assessed by Western
immunoblot analysis using antibodies that recognize T-bet
and GAPDH proteins. Cell pellets were lysed with mamma-
lian cell lysis kit (Sigma, Munich, Germany; cat# MCL1-1KT)
and denatured proteins (30 mg) were subsequently separated
by sodium dodecyl sulphate-polyacrylamide gel electrophor-
esis on 10% vertical slab gels and transferred to Hybond
electrochemoluminescence (ECL) membranes (Amersham
Biosciences, Freiburg, Germany). The nitrocellulose was
incubated for 1 h at 25 1C in 25mM Tris-buffered saline
(TBS; pH 7.6; 150mM NaCl) containing 0.1% Tween 20 (TBS-
Tween 20). and 10% w/v nonfat milk and then for 2 h in TBS-
Tween 20 containing 3% bovine serum albumin and primary
antibodies directed against either T-bet (Santa Cruz CA,
USA; cat# sc-21763), diluted 1:200 or GAPDH (Stressgen,
Victoria, BC, Canada, cat# CSA-335) diluted 1:1000. Follow-
ing three 10-min washes in TBS-Tween 20, the membranes
were incubated for 60min at 25 1C with rabbit anti-mouse
HRP-conjugated immunoglobulin (Ig) G (Dako, Glostrup,
Denmark, cat# 54549) diluted 1:2000 in TBS-Tween 20
supplemented with 1% nonfat milk for T-bet and also for
GAPDH, and subsequently visualized by ECL. The relevant
bands were quantified using a transilluminator with a light
converter plate (coupled with video camera and computer),
BioDocAnalyze 2.0 software (Biometra, Go¨ttingen, Ger-
many) normalized to the house-keeping protein GAPDH.Data analysis
Data are represented as mean7SEM. Data were analyzed by
Student’s t-test for paired data or by one-way ANOVA/
Bonferroni multiple comparison test. The null hypothesis
was rejected when Po0:05.Results
IL-12-induced T-bet mRNA expression (real time
PCR)—effect of PD 098059, SB 203580 and
dexamethasone
There was no significant difference in basal (non-stimulated)
and anti-CD3/anti-CD28-pretreated T-bet mRNA expression
normalized to EF-1a in normal and asthmatic T-cells (T-bet/
EF-1a ratio normals: basal: 0.004470.0015; anti-CD3/anti-
CD28: 0.0170.003, n ¼ 10; T-bet/EF-1a ratio asthmatics:
basal: 0.004170.0005; anti-CD3/anti-CD28: 0.01170.0022;
P40:05; n ¼ 10; Fig. 1).
IL-12 (10 ng/ml) induced an increase in T-bet mRNA
expression of anti-CD3/anti-CD28 pretreated T-cells from
asthmatics compared with normals (0.03370.009 vs.
0.01270.0024.; n ¼ 10; Po0:05). Stimulation with IL-12
(10 ng/ml) did not induce further T-bet mRNA expression of
anti-CD3/anti-CD28 pretreated T-cells from normals
(0.01270.0024 vs. 0.0170.003; n ¼ 10; P40:05).
PD 098059 (10 mM) had no inhibitory effect on IL-12-
induced increased T-bet mRNA expression in T-cells from
asthmatics (0.03370.01; P40:05, vs. IL-12 alone; n ¼ 10).However, the inhibition of the increased IL-12 induced T-bet
mRNA expression in T-cells from asthmatics by SB 203580
(10 mM) was 100% (0.015370.007 vs. 0.03370.009;
Po0:05; n ¼ 10), indicating that p38MAPK pathway may
play a more basic role in the regulation of T-bet transcrip-
tion in asthma.
Dexamethasone (106 M) reduced IL-12-induced T-bet
mRNA expression in asthmatic T-cells nearly completely
(T-bet/EF-1a ratio: 0.009970.002 vs. 0.03370.009, Po0:05;
n ¼ 10); (Fig. 1). PD 098059 and SB 203580 did not modulate
the dexamethasone-induced inhibition of T-bet mRNA
expression in T-cells from asthmatics and normals (Fig. 1).
IL-12-induced T-bet protein expression (Western
blotting)—effect of PD 098059, SB 203580 and
dexamethasone
Under basal (non-stimulated; data not shown) and under
anti-CD3/anti-CD28 pre-treated conditions, expression of
T-bet was detectable by Western blotting (Fig. 2) and was
normalized to the house-keeping protein GAPDH (Fig. 2).
IL-12 (10 ng/ml) induced a significant increase in T-bet
expression in asthmatic T-cells compared with normals
(T-bet/GAPDH ratio: normals: 0.1970.03 vs. asthma:
0.5770.1; n ¼ 10, Po0:05).
PD 098059 (10 mM) had no inhibitory effect on IL-12-
induced increased T-bet protein expression in asthmatic
T-cells (0.7670.2 vs. 0.5770.1; P40:05, n ¼ 10). However,
the inhibition of the increased IL-12 induced T-bet protein
expression in T-cells from asthmatics by SB 203580 (10mM)
was 80% (0.2170.04 vs. 0.5770.1; Po0:05; n ¼ 10),
indicating that p38MAPK pathway may play also a more
basic role in the regulation of T-bet expression on post-
transcriptional level in asthma.
Dexamethasone (106 M) reduced IL-12-induced T-bet
protein expression in asthmatic T-cells nearly completely
(T-bet/GAPDH ratio: 0.1470.04 vs. 0.5770.1, Po0:05;
n ¼ 10); (Fig. 2). PD 098059 and SB 203580 did not modulate
the Dexamethasone-induced inhibition of T-bet protein
expression in T-cells from asthmatics and normals (Fig. 2).
IL-12-induced generation of IFNc—effect of PD
098059, SB 203580 and dexamethasone
There was no difference in the basal and anti-CD3/anti-
CD28-pretreated generation of IFNg in human peripheral
blood T-lymphocytes from adult atopic asthmatics (anti-
CD3/anti-CD28: 305.37131.8 pg/ml; n ¼ 10) compared with
adult non-atopic normals (anti-CD3/anti-CD28: 273.27
111.2 pg/ml; n ¼ 10; graph not shown). IL-12 (10 ng/ml) in-
duced an increase in IFNg release in T-cells and this to the
same extent in normals (714.97233.0 pg/ml; n ¼ 10) and in
the asthmatics (732.77354.7 pg/ml; n ¼ 10; P40:05)
(graph not shown).
PD 098059 (10 mM), an inhibitor of the upstream activator
of ERK-1 and ERK-2, suppressed IL-12-induced IFNg release
by 41.174.5% in T-cells from normals but only by 20.976.3%
in asthma (Po0:05; n ¼ 10; Fig. 3) indicating a diminished
TH1-related ERK-modulation in asthma. SB 203580 (10 mM),
an inhibitor of the a- and b-isoform of p38MAPK, was more
effective on IFNg release, causing an inhibition of
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Figure 2 Shows representative original Western blots of anti-CD3/anti-CD28 pre-incubated (500 ng/ml each) and IL-12 (10 ng/ml)
induced T-bet- and GAPDH-protein-expression alone and in the presence of PD 098059 (10 mM), SB 203580 (10 mM) and dexamethasone
(106 M) from peripheral blood T-lymphocytes of a non-atopic normal and an atopic asthmatic volunteer.
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Figure 1 RT-real-time PCR showing basal, anti-CD3/anti-CD28 pre-incubated (500 ng/ml each) and interleukin-12 (IL-12; 10 ng/ml)
stimulated T-bet mRNA expression normalized to EF-1a alone and in the presence of PD 098059 (10 mM); SB 203580 (10 mM) and
dexamethasone (106 M) from peripheral blood lymphocytes of 10 normal and 10 asthmatic individuals. Data are presented as
mean7SEM from separate experiments.
A. Koch et al.132653.877.4% in T-cells from normals and 64.375.1% in T-cells
from asthmatics without statistical significance between
both groups (n ¼ 10; P40:05; Fig. 3).
Dexamethasone (106 M) inhibited IL-12-induced IFNg
release by 34.5710.8% in T-cells from normals (n ¼ 10)
and by 52.1717.3% in asthmatics (n ¼ 10; P40:05; Fig. 3).
Interestingly, there was an additional inhibitory effect on
IFNg release when PD 098059 or SB 203580 were added in the
presence of dexamethasone and this was statistically
significant by SB 203580 in T-cells from normals
(74.777.1% vs. 34.5710.8%; Po0:05; n ¼ 10; Fig. 3).Discussion
In this study, we could shown that the TH1-specific
transcription factor T-bet was constitutively expressed in
peripheral blood T-lymphocytes without differences be-tween non-atopic normals and atopic asthmatic volunteers.
Furthermore, we demonstrated for the first time that the I
L-12-induced T-bet mRNA- and protein expressions were
significantly increased in asthmatic peripheral blood T-cells
compared with normals.
Interestingly, the elevated T-bet expression seen in
asthmatic but not in normal T-cells did not correspond to
the increased IFNg release seen in both groups. So we
speculate that (1) IL-12 signaling is able to induce IFNg
production independently of T-bet mRNA and protein
expression in TH1 cells and/or (2) IL-12 receptor b2 chain
and/or STAT4 expressions could be down-regulated in
asthmatic T-cells by elevated GATA-3 expression7,20,25 and/
or (3) elevated GATA-3 expression in asthma7 may inhibit
IFNg expression20 (Fig. 4).
Our results are consistant with a study from Ylikoski
et al.23 demonstrating that a high T-bet protein expression
in human CD4+ T-cells from the cord blood of healthy
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Figure 3 Inhibitory effect of PD 908059 (10 mM), SB 203580 (10 mM) and dexamethasone (106 M) on maximal IL-12 (10 ng/ml)
induced IFNg release in peripheral blood lymphocytes from non-atopic normal (n ¼ 10) and atopic asthmatic (n ¼ 10) subjects. The
amount of IFNg released into the culture supernatant after 72 h was measured by sandwich enzyme-linked immunosorbent assay.
Data are presented as mean7SEM from separate experiments.
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tion.
Moreover, Usui et al.20,25 could shown that naı¨ve T-bet /
 CD4+ T-cells from mice were able to produce IFNg, and
that the IFNg promoter accessibility could proceed in the
absence of T-bet under IL-12 and anti-IL-4 stimulation. This
could be one explanation why in our study IL-12 stimulation
was followed by an increase in IFNg release but without
increase in T-bet expression seen in normal T-cells, indicat-
ing that IL-12 did skew naive Th cells towards TH1 although it
did not augment T-bet.
Recently, Usui et al.25 could demonstrate that naı¨ve
T-cells from mice tend toward TH2 differentiation through
induction of GATA-3 and subsequent down-regulation of
STAT4/IL-12Rb2 chain unless GATA-3 levels or function is
regulated by T-bet. The authors therefore supposed that the
principal function of T-bet in developping TH1 cells may be
to negatively regulate GATA-3 rather than to positively
regulate the IFNg gene.
Demonstrating that T-bet is not essential for IL-12Rb2
chain expression, Afkarian et al.21 suggest that T-bet has an
indirect influence on such expression through its ability
to obviate GATA-3 effects on STAT4. Indeed, Usui et al.
have shown that STAT4 signaling can induce IL-12Rb2
chain expression in the absence of T-bet and that GATA-3
down-regulation of the IL-12Rb2 chain occurs through down-
regulation of STAT4.20,25
It is well known, that GATA-3 expression is increased in
asthmatic T-cells.7 We speculate that elevated GATA-3 levels
in asthma were followed by elevated T-bet expression seenin our study to further negatively regulate GATA-3 in asthma
(Fig. 4). Indeed, Erpenbeck et al.22 reported that in healthy
control subjects, the expressions of GATA-3, c-maf and T-bet
in BAL cells were unchanged after saline or allergen
challenge. In contrast, GATA-3, c-maf and T-bet were
significantly upregulated after allergen challenge but not
saline challenge in the asthmatic patients. This was
surprisingly, because they expected a down-regulation of
T-bet after allergen challenge in asthmatic T-cells, but the
opposite was the case. The authors speculate that increased
T-bet expression after allergen challenge in asthma might
not only result from activated TH1 but also from activated
TH2 cells and suggest that T-bet mRNA is not specific for a
TH1-type inflammatory response.
Interestingly, Ho¨hler et al.35 reported that the TH cell
polarization and differentiation of TH1 cells may under the
control of cytokines and transcription factors with mainly
locally and genetically determined activity. Signature
cytokines and cytokine signaling events of TH1 rather than
TH2 cells may be genetically determined and implicate that
TH2-associated diseases in humans such as asthma might be
due to genetic variations in TH1 cytokine regulation via
T-bet. Ho¨hler et al. have done a twin study and found low
variability of intrapair differences in monozygotic (MZ) twins
compared with dizygotic (DZ) twins for IFNg and T-bet,
indicative of a strong genetic component in the expression
of these TH1-associated proteins. There was in contrast little
or no evidence for a genetic effect on TH2 differentiation,
however. The fact that IL-12 stimulation was followed by an
increase in T-bet expression of asthmatic T-cells but not in
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determined mechanism further on TH1 level.
We speculate that the increased GATA-3 expression in
asthmatic T-cells were followed by a decrease in STAT-4
expression and this was followed by an increased down-
regulation of IL-12Rb2 chain expression responsible for no
further increase in IFNg release compared with normals.7,20,25IFN γ 
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(B)This could be one possible explanation why changes in T-bet
mRNA between naı¨ve and asthmatic T-cells did not correspond
to changes in IFNg production seen in our study. Moreover,
elevated GATA-3 levels might downregulate IFNg expression in
asthmatic T-cells while increasing IL-4 and IL-5 expression.36
We next investigated the role for phosphorylation of
extracellular signal-regulated kinases (ERKs) ERK-1, ERK-2
and p38MAPK by studying the ability of their respective
inhibitors PD 098059 and SB 203580 to regulate T-bet mRNA
transcription and protein expression and IFNg release.
Evidence for this possibility has recently come from Agrawal
et al.37 who have shown that ERK 1 / mice display a bias
toward TH1 type immune response with higher IFNg production
and lower IL-5 production in MOG35-55-primed T-cells
indicating that ERK1 may modify the TH1/TH2 balance in
T-cells as a negative regulator of TH1 immune responses.
Whereas PD 098059 had no inhibitory effect on IL-12-
induced T-bet expression in asthmatic and normal T-cells
(Fig. 1) but decreased IFNg release by 40% in asthmatic and
to a lesser extent in normal T-cells (20%) (Fig. 3), the
inhibitory effect of SB 203580 on IL-12 induced T-bet
mRNA and protein expression in asthmatic T-cells was
100% (Figs. 1 and 2). In contrast there was no inhibitory
effect of SB 203580 on T-bet expression in normal T-cells but
SB 203580 decreased IFNg release by 60% and this without
differences between groups, indicating that (1) p38MAPK
pathway rather than ERK-pathway may play a more basic
role in the regulation of T-bet transcription and protein
expression in asthma and (2) that ERK- and p38MAPK
activation may modulate the IFNg expression independently
of the T-bet signaling pathway and this regulatory role of
ERK-1/-2 on IFNg release may impaired in asthma.Figure 4 Naive peripheral blood lymphocytes may tend toward
TH2 differentiation through induction of GATA-3 and subsequent
down-regulation of STAT4/IL-12Rb2 chain unless GATA-3 levels
or function is regulated by T-bet20,25 (Panel A) indicating that
the principal function of T-bet in developing TH1 cells is to
negatively regulate GATA-3 rather than to positively regulate
IFNg gene.
IL-12 (10 ng/ml) had no effect on T-bet expression but promotes
TH1 response through an increase in IFNg release. There was a
decrease in IL-12 induced IFNg release but no effect on T-bet
expression in the presence of the specific ERK-inhibitor PD
098059 (10 mM), the specific p38MAPK-inhibitor SB 203580
(10 mM) and dexamethasone (DEX; 106 M).
Panel B: Stimulation with IL-12 (10 ng/ml) increased T-bet
expression in asthmatic T-cells and this could be inhibited
nearly completely in the presence of SB 203580 (10 mM) and Dex
(106 M). IL-12 induced an increase in IFNg release in asthmatic
T-cells and this to the same extent as in normals.
In contrast PD 098059 (10 mM) did not modulate the elevated
T-bet expression in asthma. In the presence of SB 203580
(10 mM) and DEX (106 M) the IFNg release was reduced and this
to the same extent as in normals. In contrast PD 098059 (10 mM)
modulated IFNg release in asthma to a lesser extent compared
with normals. We speculate that increased GATA-3 levels in
asthmatic T-cells decreased STAT-4 expression followed by a
decrease in IL-12 receptor b2 chain expression, and therefore
no additional increase in IFNg release could be found compared
with normals.
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reporting that ERK activity in asthmatic mice was significantly
higher as compared with normal mice. Moreover, they could
show that a selective inhibitor of MAPK/ERK kinase U0126
suppressed OVA-induced airway hyperresponsiveness to in-
haled methacholine in an in vivo mouse asthma model and
reduced the serum levels of total IgE, lung tissue eosinophilia,
airway mucus production and expression of VCAM-1 in lung
tissues, implicating that inhibition of ERK-signaling pathway
may have potential anti-inflammatory effects and therefore
the authors speculate for a therapeutic potential for the
treatment of allergic airway inflammation.38
Corticosteroids are the most effective anti-inflammatory
therapy for asthma. The predominant effect of corticoster-
oids is to switch off multiple inflammatory genes encoding
cytokines and other mediators that have been activated
during the inflammatory process. There is been considerable
interest in how corticosteroids affect the TH1-specific T-bet
signal transduction pathway including the IFNg release in
T-cells from normals and asthmatics.
In this study, we could demonstrate that dexamethasone
reduced the increased IL-12-induced T-bet mRNA expression
in asthmatic T-cells nearly completely without additional
effects of the specific MAPkinase inhibitors PD 098059 and SB
203580 (Fig. 1). However, dexamethasone reduced the IFNg
release only by 50% in asthmatic and normal T-cells
indicating that (1) IFNg is regulated not only by T-bet but
also by additional pathways and (2) that the inhibitory
effect of dexamethasone on T-bet expression is increased in
asthma. In the context of our speculation, that an increase
in T-bet expression may be necessary to counter-regulate
the increased GATA-3 level in asthma, the ‘‘anti-inflamma-
tory’’ effect of dexamethasone on TH1 response should be
seen more critically and needs to be further investigated.
Furthermore, an additional inhibition of IFNg release was
obtained when PD 098059 or SB 203580 were added to
dexamethasone, indicating that inhibition of p38MAPK and
of ERK-1/-2 pathways could potentiate the inhibitory effect
of dexamethasone on IFNg release.
This is consistent with findings from Tsitoura et al.39
demonstrating that dexamethasone effectively suppressed
T-cell receptor (TCR)-induced proliferation of naı¨ve CD4+
T-cells. However, enhancement of TCR signaling by CD28-
mediated costimulation abrogated the suppressive effect of
dexamethasone. In particular, costimulatory signaling via
ERK was essential for the development of T-cell resistance to
dexamethasone, because selective blockade of ERK signal
transduction abolished the costimulation-induced resis-
tance. The authors speculate that, in the immune system,
by regulating the degree of local costimulation through ERK
can modify the effect of glucocorticoids on T-cells.39
In conclusion, the therapeutic benefit of inhibitors of the
ERK- and p38MAPK pathways and of the anti-inflammatory
drug dexamethasone on TH1-specific T-bet expression and
IFNg release in asthma seems to be critical and needs to be
further investigated.Acknowledgments
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